ArticleGynecologic oncology2019

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Elena Bonazzoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.